Phase 3 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific inherited blood clotting condition before joining the trial — this includes having one copy of the Factor V Leiden gene change, one copy of the prothrombin gene change, Protein C deficiency, or Protein S deficiency.
- People who were on bed rest for 7 or more days during pregnancy, spending about 90% of waking hours in bed.
- Alternatively, people who meet at least TWO of the following conditions may also be eligible:
- A pre-pregnancy body weight classified as obese (BMI of 30 or above)
- Smoking during the current pregnancy or in the 3 months before pregnancy
- A previous history of a blood clot in a surface vein
- Preeclampsia (a blood pressure complication during pregnancy)
- The current pregnancy ending in a stillbirth (pregnancy loss after 20 weeks)
- An unplanned caesarean delivery (not a scheduled caesarean)
- A baby born smaller than expected for their gestational age (below the 3rd percentile)
- An infection around the time of or after delivery, confirmed by fever, blood tests, or positive blood cultures
- Heavy bleeding after delivery (1,000 mL or more, regardless of how the baby was delivered)
Who may not be able to join:
- People who are more than 48 hours past delivery at the time of joining the trial
- People who have already received more than one dose of a blood-thinning injection called LMWH since delivery
- People whose doctor has determined they need blood-thinning medication after delivery — this may include people with a previous blood clot, a mechanical heart valve, antiphospholipid syndrome, or a higher-risk inherited clotting condition such as antithrombin deficiency, two copies of the Factor V Leiden gene change, two copies of the prothrombin gene change, or a combination of two or more clotting conditions
- People whose doctor has determined they need to take aspirin after delivery — this may include people with a history of heart attack, stroke, or a mini-stroke (TIA)
- People who are experiencing active bleeding at the time of joining (normal vaginal bleeding after birth is not included)
- People with a known medical condition that their doctor considers a reason to avoid aspirin or LMWH, including a known allergy to either medication
- People under 18 years of age
- People who are unable to give consent or who have declined to give consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Leslie Skeith, MD, University of Calgary
Phone: 403-944-5246
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Symptomatic VTE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.